Cardiovascular Diabetology (Mar 2023)
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
- Oliver Schnell,
- Tadej Battelino,
- Richard Bergenstal,
- Andreas L. Birkenfeld,
- Antonio Ceriello,
- Alice Cheng,
- Melanie Davies,
- Steve Edelman,
- Thomas Forst,
- Francesco Giorgino,
- Jennifer Green,
- Per-Henrik Groop,
- Samy Hadjadj,
- Hiddo J.L.Heerspink,
- Marcus Hompesch,
- Baruch Izthak,
- Linong Ji,
- Naresh Kanumilli,
- Boris Mankovsky,
- Chantal Mathieu,
- Martin Miszon,
- Reem Mustafa,
- Michael Nauck,
- Roberto Pecoits-Filho,
- Jeremy Pettus,
- Kari Ranta,
- Helena W. Rodbard,
- Peter Rossing,
- Lars Ryden,
- Petra-Maria Schumm-Draeger,
- Scott D. Solomon,
- Jan Škrha,
- Pinar Topsever,
- Tina Vilsbøll,
- John Wilding,
- Eberhard Standl
Affiliations
- Oliver Schnell
- Forschergruppe Diabetes e. V., Helmholtz Center Munich
- Tadej Battelino
- University Medical Center
- Richard Bergenstal
- International Diabetes Center at Park Nicollet, Health Partners
- Andreas L. Birkenfeld
- Department of Internal Medicine IV, University Clinic Tübingen
- Antonio Ceriello
- IRCCS MultiMedica
- Alice Cheng
- Credit Valley Hospital
- Melanie Davies
- Diabetes Research Centre, University of Leicester
- Steve Edelman
- Taking Control of Your Diabetes
- Thomas Forst
- CRS Clinical Research Services Mannheim GmbH
- Francesco Giorgino
- Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro
- Jennifer Green
- Division of Endocrinology, Department of Medicine and Duke Clinical Research Institute, Duke University School of Medicine
- Per-Henrik Groop
- Department of Nephrology, University of Helsinki and Helsinki University Hospital
- Samy Hadjadj
- Thorax Institute, University Hospital of Nantes
- Hiddo J.L.Heerspink
- Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen
- Marcus Hompesch
- ProSciento Inc.
- Baruch Izthak
- Clalit Health Services and Technion Faculty of Medicine
- Linong Ji
- Peking University People’s Hospital
- Naresh Kanumilli
- Manchester University Foundation Trust
- Boris Mankovsky
- Shupyk National Medical Academy of Postgraduate Education
- Chantal Mathieu
- Department of Endocrinology, Catholic University Leuven
- Martin Miszon
- Sciarc GmbH
- Reem Mustafa
- Division of Nephrology and Hypertension, Medical Center, University of Kansas
- Michael Nauck
- Diabetes Division, St. Josef Hospital, Ruhr-University Bochum
- Roberto Pecoits-Filho
- Pontifical Catholic University of Paraná
- Jeremy Pettus
- Altman Clinical and Translational Research Institute (ACTRI)
- Kari Ranta
- Eli Lilly and Company
- Helena W. Rodbard
- Endocrine and Metabolic Consultants
- Peter Rossing
- Steno Diabetes Center Copenhagen
- Lars Ryden
- Department of Medicine K2, Karolinska Institute
- Petra-Maria Schumm-Draeger
- Center Internal Medicine Fünf Höfe
- Scott D. Solomon
- Cardiovascular division, Brigham and Women’s Hospital
- Jan Škrha
- Third Medical Department and Laboratory for Endocrinology and Metabolism, First Faculty of Medicine, Charles University
- Pinar Topsever
- Department of Family Medicine, Acıbadem Mehmet Ali Aydınlar University School of Medicine
- Tina Vilsbøll
- Steno Diabetes Center Copenhagen
- John Wilding
- Institute of Life Course and Medical Sciences, University of Liverpool
- Eberhard Standl
- Forschergruppe Diabetes e. V., Helmholtz Center Munich
- DOI
- https://doi.org/10.1186/s12933-023-01788-6
- Journal volume & issue
-
Vol. 22,
no. 1
pp. 1 – 12
Abstract
Abstract The 8th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Kidney, and Glycemic Outcomes was held virtually on November 10–12, 2022. Following the tradition of previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed outcomes trials as well as key trials important to the cardiovascular (CV) field. This year’s focus was on the results of the DELIVER, EMPA-KIDNEY and SURMOUNT-1 trials and their implications for the treatment of heart failure (HF) and chronic kidney disease (CKD) with sodium-glucose cotransporter-2 (SGLT2) inhibitors and obesity with glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. A broad audience of primary care physicians, diabetologists, endocrinologists, cardiologists, and nephrologists participated online in discussions on new consensus recommendations and guideline updates on type 2 diabetes (T2D) and CKD management, overcoming clinical inertia, glycemic markers, continuous glucose monitoring (CGM), novel insulin preparations, combination therapy, and reclassification of T2D. The impact of cardiovascular outcomes on the design of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) trials, as well as the impact of real-world evidence (RWE) studies on the confirmation of CVOT outcomes and clinical trial design, were also intensively discussed. The 9th Cardiovascular Outcome Trial Summit will be held virtually on November 23–24, 2023 ( http://www.cvot.org ).
Keywords
- Cardiovascular disease
- Chronic kidney disease
- Diabetes
- GIP/GLP-1 receptor agonist
- Heart failure
- Obesity
